Excalibur Management Corp Buys 113 Shares of Johnson & Johnson (NYSE:JNJ)

Excalibur Management Corp raised its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 0.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,212 shares of the company’s stock after purchasing an additional 113 shares during the period. Johnson & Johnson accounts for approximately 3.1% of Excalibur Management Corp’s investment portfolio, making the stock its 6th biggest position. Excalibur Management Corp’s holdings in Johnson & Johnson were worth $7,127,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Patron Partners LLC boosted its position in shares of Johnson & Johnson by 12.7% in the first quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock valued at $1,174,000 after acquiring an additional 747 shares during the period. Tandem Investment Advisors Inc. boosted its position in shares of Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after acquiring an additional 15,003 shares during the period. Argent Advisors Inc. boosted its position in shares of Johnson & Johnson by 6.6% in the first quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after acquiring an additional 1,218 shares during the period. Exeter Financial LLC boosted its position in shares of Johnson & Johnson by 3.2% in the first quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock valued at $4,684,000 after acquiring an additional 819 shares during the period. Finally, Winthrop Advisory Group LLC boosted its position in shares of Johnson & Johnson by 3.7% in the first quarter. Winthrop Advisory Group LLC now owns 9,090 shares of the company’s stock valued at $1,611,000 after acquiring an additional 325 shares during the period. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating for the company. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research report on Friday, July 8th. SVB Leerink cut their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Finally, UBS Group cut their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Stock Up 0.2 %

JNJ stock opened at $174.52 on Monday. The stock has a market capitalization of $459.23 billion, a P/E ratio of 25.40, a price-to-earnings-growth ratio of 3.28 and a beta of 0.63. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a 50-day moving average price of $175.95 and a 200-day moving average price of $174.46.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter in the prior year, the firm posted $2.48 earnings per share. The firm’s revenue was up 3.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.